Jubilant Pharmova Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "Press Release".
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova reported FY26 revenue of Rs. 8,280 Cr, up 14% YoY, driven by strong growth in CDMO Sterile Injectables (38% growth to Rs. 1,755 Cr) and other segments. EBITDA grew 8% to Rs. 1,326 Cr, but EBITDA margins declined 99 bps to 15.9% due to temporary shutdown of the Montreal CDMO facility following FDA observations. Normalised PAT grew 7% to Rs. 442 Cr. The company onboarded one of the world's largest oncology products on its Spokane Line 3 and proposed a dividend of Rs. 5 per share. Management guided that EBITDA margins will strengthen from H2'FY27 onwards as Montreal production stabilizes. Net Debt/EBITDA stood at 1.3x. The company is on track toward its Vision 2030 target of Rs. 13,500 Cr revenue and 23-25% EBITDA margins.
The stock shows solid revenue growth momentum, but margin pressure from the Montreal facility is a near-term concern. The large oncology product win and accelerating CDMO pipeline are positive. Management's visibility on margin recovery from H2'FY27 provides a clear timeline for improvement.